Trevi Therapeutics, Inc.TRVINASDAQ
LOADING
|||
R&D Expense Growth Accelerating
Trending higher, above historical average.
Left:
||||
Year-over-year research & development expense growth
Latest
66.27%
↑ 142% above average
Average (8y)
27.43%
Historical baseline
Range
High:130.88%
Low:-13.71%
Volatility
527.2%
High variability
| Period | Value |
|---|---|
| 2024 | 66.27% |
| 2023 | 19.41% |
| 2022 | -13.71% |
| 2021 | 2.94% |
| 2020 | 15.46% |
| 2019 | 37.43% |
| 2018 | 130.88% |
| 2017 | -11.83% |
| 2016 | 0.00% |